Assessment of N terminal pro BNP levels in congestive heart failure patients
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 4707-4711
AbstractBackground: Natriuretic peptides (NPs) have been found to be useful markers in differentiating acute dyspneic patients presenting to the emergency department (ED) and emerged as potent prognostic markers for patients with congestive heart failure. The present study was conducted to assess N terminal pro BNP levels in congestive heart failure patients.
Materials & Methods: 65 congestive heart failure patients of both genders were categorised into three groups:those with LVEF ≥50% were categorised as HFpEF (group I), those with<40% were categorised as HFrEF (group II) and patients with LVEFrange of 40%–49% were defined as heart failure with midrangeEF (HFmrEF) (group III). NT-proBNP was measured using the Roche Elecys proBNP assay.
Results: Out of 65 patients, males were 35 and females were 30. The mean age was 65.3 years in group I, 64.2 years in group II and 62.5 years in group III. Diabetes was seen in 10 in group I, 8 in group II and 7 in group III. Hypertension in 3 in group I, 6 in group II and 8 in group III and COPD in 1 in group I, 3 in group II and 5 in group III. The difference was non- significant (P> 0.05). The mean SBP at admission (mm Hg) was 143.2, 138.5 and 134.2, DBP at admission (mm Hg) was 86.2, 80.4 and 78.6, heart rate at admission (bpm) was 92, 94 and 95, left ventricular ejection fraction was 56, 42 and 28. NT-proBNP at admission was 4423.5pg/mL, 5062.4pg/mL and 7126.4pg/mL and NT-proBNP at discharge was 2145.2pg/mL, 2762.4pg/mL and 3650.2 in group I, group II and group III respectively.
Conclusion: Absolute and percentage change in N-terminal proB-type natriuretic peptide (NT-proBNP) levels in patients hospitalised for acute decompensated heart failure is of prognostic significance
- Article View: 5
- PDF Download: 20